French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that China's National Medical Products Administration has approved two Sanofi-licensed medicines: Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control.

Myqorzo, a selective cardiac myosin inhibitor, was approved based on positive results from the pivotal SEQUOIA-HCM phase 3 study in symptomatic patients. Redemplo, a small-interfering RNA (siRNA) therapy targeting apoc-III to reduce triglyceride levels, was approved following the pivotal PALISADE phase 3 study in patients with genetically confirmed or clinically diagnosed FCS.

Sanofi obtained exclusive rights to develop and commercialise Myqorzo in Greater China in December 2024 through an agreement with Corxel Pharmaceuticals, which had acquired the rights from Cytokinetics. In August 2025, Sanofi acquired the Greater China rights to Redemplo from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.